Search PubMed⌕ Search

Biomedical subjects

K Frost-Larsen

Publications and source records attributed to K Frost-Larsen.

33 records · Page 2Linked to original sources
PubMed1981

Bromhexine treatment of Sjögren's syndrome: effect on lacrimal and salivary secretion, and on proteins in tear fluid and saliva.

In a randomized clinical study, 32 patients with Sögren's syndrome (SS were given placebo/bromhexine (Bisolvon) 48 mg daily for 3 weeks. Various ophthalmological and oral variables as well as different proteins in the tear fluid and saliva were registered. Bromhexine stimulated the tear secretion significantly, presumable without changing the protein composition of the tear fluid. In contrast to other proteins in saliva the IgM concentration decreased in patients with high pre-treatment values. Bromhexine may be of valuable help in the treatment of some patients with SS.

Adult↗
PubMed1980

Fluorescein angiography in diabetic children. A follow-up.

The present study is a fluorescein angiographic follow-up of 60 diabetic children (aged 12 -- 16 years). At the follow-up, with two-thirds of the children in pubescence, fluorescein angiography revealed diabetic retinopathy in 10 (17%) of the children. The results indicate puberty as a probable determining factor influencing the onset of the diabetic retinopathy.

Adolescent↗
PubMed1980

Oscillatory potential and nyctometry in insulin-dependent diabetics.

The study draws a comparison between the oscillatory potential of the electroretinogram and the initial dark-adaptation measured by nyctometry, with the aim of assessing the predictive value of nyctometry in juvenile diabetics. The study included 61 insulin-dependent juvenile diabetics, aged 18-49 years, with a disease duration of more than five years. A statistically highly significant correlation could be demonstrated between alterations in the oscillatory potential and in the initial dark-adaptation. The results justify the assumption that nyctometry can be used as an easily handled clinical tool in selecting those at risk of developing proliferative retinopathy in their subsequent 6-8 years.

Adolescent↗
PubMed1978

Sjörgren's syndrome treated with bromhexine: a randomised clinical study.

Existing treatment for Sjögren's syndrome is unsatisfactory, and uncontrolled observations have suggested that bromhexine may be effective. Twenty-nine patients with Sjögren's syndrome were therefore assigned to two randomised double-blind crossover trials with bromhexine and placebo, each comprising two two-week periods. In the first trial bromhexine 24 mg/day was given by mouth; in the second the dose was increased to 48 mg/day. After each treatment period the Schirmer test response, break-up time, Bijsterveld score, and the time taken for the patient to eat a dry biscuit were recorded, as well as the patient's estimate of moistness in the eyes and mouth. In the second (higher-dose) trial values on the Schirmer test were significantly higher after bromhexine than after placebo and the break-up time was also increased after bromhexine, which suggested that the drug has a dose-dependent effect on lacrimal gland secretion in Sjögren's syndrome. It had no effect on salivary gland function. Bromhexine is therefore valuable in the treatment of Sjögren's syndrome.

Bromhexine↗